» Articles » PMID: 35785822

Bone Remodeling in Mandible of Wistar Rats with Diabetes Mellitus and Osteoporosis

Overview
Journal Eur J Dent
Publisher Thieme
Specialty Dentistry
Date 2022 Jul 5
PMID 35785822
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives:  This study aimed to determine some of bone molecular expressions and its possible bone remodeling pathway between diabetes mellitus (DM) and osteoporosis model in the mandibular bone of Wistar rats.

Materials And Methods:  Twenty-seven female Wistar rats were divided randomly into control and treatment groups. Treatment groups were injected with streptozotocin intraperitoneally to induce DM (P1) and underwent bilateral ovariectomy to generate osteoporosis (P2). All groups were terminated after 12 weeks. Immunohistochemical and hematoxylin-eosin staining were performed to determine the expression of Runt-related transcription factor 2 (RUNX2), Osterix, vascular endothelial growth factor (VEGF), receptor activator of nuclear factor κB ligand (RANKL), osteoprotegerin (OPG), tartrate-resistant acid phosphatase (TRAP), and observed the osteoblast and osteoclast. Statistical analysis was performed using one-way analysis of variance.

Results:  The lowest mean of RUNX2 and VEGF expression was found in the P2 group. The lowest mean of Osterix expression was found in the P1 group. Both P1 and P2 groups of osteoblast/osteoclast ratio were decreased. There were no significant differences in the expression of TRAP between all groups; however, increased expression of RANKL/OPG ratio was only found in the P2 group.

Conclusion:  DM and osteoporosis induce changes in the bone remodeling pathway which are represented by a decrease in osteoblast biomarkers and an increase in osteoclast biomarkers.

Citing Articles

The Potential Therapeutic Effects of Platelet-Derived Biomaterials on Osteoporosis: A Comprehensive Review of Current Evidence.

Amiri M, Farshidfar N, Miron R, Dziedzic A, Hamedani S, Daneshi S Int J Biomater. 2023; 2023:9980349.

PMID: 38098766 PMC: 10721351. DOI: 10.1155/2023/9980349.

References
1.
Xu F, Dong Y, Huang X, Li M, Qin L, Ren Y . Decreased osteoclastogenesis, osteoblastogenesis and low bone mass in a mouse model of type 2 diabetes. Mol Med Rep. 2014; 10(4):1935-41. DOI: 10.3892/mmr.2014.2430. View

2.
Raehtz S, Bierhalter H, Schoenherr D, Parameswaran N, McCabe L . Estrogen Deficiency Exacerbates Type 1 Diabetes-Induced Bone TNF-α Expression and Osteoporosis in Female Mice. Endocrinology. 2017; 158(7):2086-2101. PMC: 5505215. DOI: 10.1210/en.2016-1821. View

3.
Miranda C, Giner M, Montoya M, Vazquez M, Miranda M, Perez-Cano R . Influence of high glucose and advanced glycation end-products (ages) levels in human osteoblast-like cells gene expression. BMC Musculoskelet Disord. 2016; 17:377. PMC: 5007697. DOI: 10.1186/s12891-016-1228-z. View

4.
Halleen J, Alatalo S, Suominen H, Cheng S, Janckila A, Vaananen H . Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res. 2000; 15(7):1337-45. DOI: 10.1359/jbmr.2000.15.7.1337. View

5.
Sassi F, Buondonno I, Luppi C, Spertino E, Stratta E, Di Stefano M . Type 2 diabetes affects bone cells precursors and bone turnover. BMC Endocr Disord. 2018; 18(1):55. PMC: 6083573. DOI: 10.1186/s12902-018-0283-x. View